AHK-Cu
- Category
- Skin & Cosmetic
- Administration routes
- Topical
- Regulatory status
- Cosmetic ingredient
What it is
AHK-Cu is a copper-binding peptide marketed for hair regrowth and skin support, said to activate the dermal papilla and support collagen. The evidence is almost entirely cell-culture and mechanism work; there are no controlled human trials, so the human case is weak. Safety data is thin, and it is contraindicated in Wilson disease, Menkes disease, and copper allergy. It is not an approved drug; it is sold in cosmetics subject to FDA cosmetic requirements and as unregulated products sold online.
Read Full recordStudied uses & evidence
Studied uses(12)
Stimulates hair follicle elongation and extends the anagen (active growth) phase
SpeculativeSingle ex vivo human follicle study measured elongation; anagen-phase extension is inferred, not directly shown.
Promotes dermal papilla cell proliferation at picomolar to nanomolar concentrations
SpeculativeDose-dependent effect shown in cultured human dermal papilla cells in one 2007 study, never replicated.
Anti-apoptotic effects: increases Bcl-2/Bax ratio, reduces cleaved caspase-3 and PARP
LowShown in vitro/ex vivo: AHK-Cu raised Bcl-2/Bax and lowered cleaved caspase-3, PARP in human dermal papilla cells.
Evidence limits
- Evidence Level
- Preclinical
The primary evidence comes from the Pyo et al. (2007) study at Seoul National University, which demonstrated AHK-Cu stimulates hair follicle elongation ex vivo and DPC proliferation in vitro using human tissue. The study employed rigorous methods including flow cytometry and Western blotting. Additional supportive evidence comes from the broader copper peptide literature, particularly the extensive GHK-Cu research base. The tripeptide class has been validated in multiple wound healing and skin regeneration studies.
Benefits = confidence in the evidence: High · Medium · Low · Speculative (High requires human randomized trials for that specific benefit)
Cautions & risk summary
General cautions
Pregnancy or breastfeeding
AbsoluteNo human reproductive safety data exists for this peptide. Effects on fetal development are unknown.
Children under 18
AbsoluteNo pediatric safety data. Not recommended for use in minors.
Known hypersensitivity
AbsoluteDiscontinue immediately if allergic reaction occurs (rash, swelling, difficulty breathing).
Risk summary(12)
Risks = level of concern: High · Moderate · Low · Theoretical
Limited long-term safety data — most studies are short-duration in vitro experiments
HighContraindicated in Wilson disease (copper metabolism disorder) and Menkes disease
ModerateContraindicated in individuals with copper allergies
ModerateInsufficient safety data for use during pregnancy and breastfeeding — avoid as precaution
ModerateLocal skin irritation (redness, itching) at application site — generally mild and transient
LowShould not be applied to broken, infected, or actively inflamed skin
LowShort in vivo half-life (<30 minutes in plasma) limits systemic bioavailability
TheoreticalRapid enzymatic degradation by proteases may reduce efficacy without proper formulation
LowPotential for allergic/hypersensitivity reactions (rare)
LowPotential copper toxicity if combined with oral copper supplements — monitor total copper intake
TheoreticalTemporary increased hair shedding in first 4-6 weeks of use (adjustment period)
TheoreticalMetallic taste or nausea reported rarely — discontinue if persistent
Theoretical
Further reading
- Overview in Full record
- Safety & interactions in Full record
- Research & benefits in Full record
- Regulation & availability in Full record
- Sources in Full record
- Frequently asked questions in Full record
This is educational content compiled from published research, not medical advice. Always consult a licensed healthcare provider before using any peptide. Medical disclaimer
Compiled from published research indexed through March 2026.